Compounders Research Compare

Actuate Therapeutics Inc(ACTU)

Biotechnology · Fort Worth, TX

$0.84-0.04 (-4.00%)

Delayed quote: Oct 6, 2026, 1:20 PM EDT

About Actuate Therapeutics Inc

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Fort Worth, TX

12 employees

actuatetherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel Schmitt

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T17:20:25.043Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:20:25.043Z.

Quote observation: 2026-10-06T17:20:05.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 20,095,323
Total debt · period ending 2026-06-30: 404,991
Cash · period ending 2026-06-30: 4,425,841
TTM free cash flow · period ending 2026-06-30: -19,836,208

FMP input reference: a29a88061d86e64317c53e71c63756e58f7ffa0b55551e6148327154cc786467

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ACTU EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ACTU Competitors' EV/FCF Ratio

Actuate Therapeutics Inc

Current

Market Cap

$20.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NextCure, Inc.

Market Cap

$20.23M

EV/FCF Ratio

N/A

TTM Avg

232.26x

3Y Avg

232.26x

5Y Avg

232.26x

P3 Health Partners Inc.

Market Cap

$19.67M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Quantum BioPharma Ltd.

Market Cap

$21.37M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Neuphoria Therapeutics Inc.

Market Cap

$18.65M

EV/FCF Ratio

N/A

TTM Avg

281.92x

3Y Avg

1403.45x

5Y Avg

1403.45x

Modular Medical, Inc.

Market Cap

$21.84M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aytu BioPharma, Inc.

Market Cap

$22.11M

EV/FCF Ratio

4.28x

TTM Avg

11.24x

3Y Avg

10.04x

5Y Avg

10.04x

LeonaBio, Inc.

Market Cap

$22.36M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cosmos Health Inc.

Market Cap

$17.79M

EV/FCF Ratio

N/A

TTM Avg

14.44x

3Y Avg

40.11x

5Y Avg

40.11x

Estrella Immunopharma, Inc.

Market Cap

$17.61M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Actuate Therapeutics Inc (ACTU)	$20.10M	N/A	N/A	N/A	N/A
NextCure, Inc. (NXTC)vs ›	$20.23M	N/A	232.26x	232.26x	232.26x
P3 Health Partners Inc. (PIII)vs ›	$19.67M	N/A	N/A	N/A	N/A
Quantum BioPharma Ltd. (QNTM)vs ›	$21.37M	N/A	N/A	N/A	N/A
Neuphoria Therapeutics Inc. (NEUP)vs ›	$18.65M	N/A	281.92x	1403.45x	1403.45x
Modular Medical, Inc. (MODD)vs ›	$21.84M	N/A	N/A	N/A	N/A
Aytu BioPharma, Inc. (AYTU)vs ›	$22.11M	4.28x	11.24x	10.04x	10.04x
LeonaBio, Inc. (LONA)vs ›	$22.36M	N/A	N/A	N/A	N/A
Cosmos Health Inc. (COSM)vs ›	$17.79M	N/A	14.44x	40.11x	40.11x
Estrella Immunopharma, Inc. (ESLA)vs ›	$17.61M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics